Search

Your search keyword '"Vandelli, M."' showing total 234 results
Start Over Author "Vandelli, M."
234 results on '"Vandelli, M."'

53. Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma

Author

Riva, G., primary, Lagreca, I., additional, Mattiolo, A., additional, Belletti, D., additional, Lignitto, L., additional, Barozzi, P., additional, Ruozi, B., additional, Vallerini, D., additional, Quadrelli, C., additional, Corradini, G., additional, Forghieri, F., additional, Marasca, R., additional, Narni, F., additional, Tosi, G., additional, Forni, F., additional, Vandelli, M. A., additional, Amadori, A., additional, Chieco-Bianchi, L., additional, Potenza, L., additional, Calabro, M. L., additional, and Luppi, M., additional

Published
2015
Full Text
View/download PDF

54. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study

Author

Palareti, G, Cosmi, B, Legnani, C, Antonucci, E, De Micheli, V, Ghirarduzzi, A, Poli, D, Testa, S, Tosetto, A, Pengo, V, Prandoni, P, Erba, N, Veropalumbo, M, Chiara, U, Prisco, D, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, Ageno, W, Tripodi, A, Imberti, D, Moia, M, Pesavento, R, Magrini, N, Marongiu, F, Zonzin, P, Piaggesi, N, Silingardi, M, Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P, Erba N, Veropalumbo MR, Chiara UM, Prisco D, Paoletti O, Falanga A, Luigi S, Donadini M, Rancan E, Quintavalla R, Ferrini PM, Santoro RC, Orlandini F, Benedetti R, Cattaneo M, Lussana F, Bertinato E, Cappelli R, Pizzini AM, Angeloni L, D'Angelo A, Crippa L, Bortolotti R, Vandelli MR, Ageno W, Tripodi A, Imberti D, Moia M, Pesavento R, Magrini N, Marongiu F, Zonzin P, Piaggesi N, Silingardi M, Palareti, G, Cosmi, B, Legnani, C, Antonucci, E, De Micheli, V, Ghirarduzzi, A, Poli, D, Testa, S, Tosetto, A, Pengo, V, Prandoni, P, Erba, N, Veropalumbo, M, Chiara, U, Prisco, D, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, Ageno, W, Tripodi, A, Imberti, D, Moia, M, Pesavento, R, Magrini, N, Marongiu, F, Zonzin, P, Piaggesi, N, Silingardi, M, Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P, Erba N, Veropalumbo MR, Chiara UM, Prisco D, Paoletti O, Falanga A, Luigi S, Donadini M, Rancan E, Quintavalla R, Ferrini PM, Santoro RC, Orlandini F, Benedetti R, Cattaneo M, Lussana F, Bertinato E, Cappelli R, Pizzini AM, Angeloni L, D'Angelo A, Crippa L, Bortolotti R, Vandelli MR, Ageno W, Tripodi A, Imberti D, Moia M, Pesavento R, Magrini N, Marongiu F, Zonzin P, Piaggesi N, and Silingardi M

Abstract

The optimal duration of anticoagulation in patients with venous thromboembolism (VTE) is uncertain. We investigated whether persistently negative D-dimers in patients with vein recanalization or stable thrombotic burden can identify subjects at low recurrence risk. Outpatients with a first VTE (unprovoked or associated with weak risk factors) were eligible after at least 3 months (12 in those with residual thrombosis) of anticoagulation. They received serial D-dimer measurements using commercial assays with predefined age/sex-specific cutoffs and were followed for up to 2 years. Of 1010 patients, anticoagulation was stopped in 528 (52.3%) with persistently negative D-dimer who subsequently experienced 25 recurrences (3.0% pt-y; 95% confidence interval [CI], 2.0-4.4%). Of the remaining 482 patients, 373 resumed anticoagulation and 109 refused it. Recurrent VTE developed in 15 patients (8.8% pt-y; 95% CI, 5.0-14.1) of the latter group and in 4 of the former (0.7% pt-y; 95% CI, 0.2-1.7; hazard ratio 5 2.92; 95% CI, 1.87-9.72; P 5 .0006). Major bleeding occurred in 14 patients (2.3% pt-y;95%CI, 1.3-3.9)whoresumedanticoagulation. Serial D-dimer measurement is suitable in clinical practice for the identification of VTE patients in whom anticoagulation can be safely discontinued. This study was registered at clinicaltrials.gov as #NCT00954395

Published
2014

60. Tenofovir treatment in HIV-related lipodystrophy syndrome. Retrospective observational forty-eight weeks follow-up study

Author

Guaraldi, Giovanni, Orlando, Gabriella, Roverato, A., DE SANTIS, Giorgio, Pedone, A., Spaggiari, A., Baccarani, A., De Fazio, D., Vandelli, M., Bertucelli, C., Beghetto, Barbara, Nardini, Giulia, Borghi, V., Grisendi, C., Bertolotti, Marco, Carubbi, Francesca, Zini, I., and Esposito, Roberto

Subjects
Lipodystrophy, Antiretroviral therapy, HIV, Lipodystrophy, liver disease, HIV, liver disease, Antiretroviral therapy
Published
2006

71. Aspirin for Preventing the Recurrence of Venous Thromboembolism

Author

Becattini, C, Agnelli, G, Schenone, A, Eichinger, S, Bucherini, E, Silingardi, M, Bianchi, M, Moia, M, Ageno, W, Vandelli, M, Grandone, E, Prandoni, P, Duranti, M, Radicchia, S, Guercini, F, Vedovati, M, Tormene, D, Perlati, M, Barbar, S, Poggio, R, Leischer, L, Galimberti, D, Leone, M, Beretta, A, Carugati, A, Braham, S, Romualdi, E, Tiscia, G, Colaizzo, D, Grilli, M, Siragusa, S, Salvi, R, Miccio, M, Ria, L, Zanatta, N, Poli, D, Camporese, G, Verlato, F, Salvi, A, Nitti, C, Santi, R, Cimminiello, C, Scannapieco, G, Barillari, G, Pasca, S, De Gaudenzi, E, Cappelli, R, Di Minno, G, Tufano, A, Frausini, G, Bova, C, Pogliani, E, Signorelli, S, Testa, S, Alatri, A, Mancuso, G, Grifoni, S, Lodigiani, C, Vedovati, MC, Leone, MF, Signorelli, SS, Lodigiani, C., BIANCHI, MARCO STEFANO, Becattini, C, Agnelli, G, Schenone, A, Eichinger, S, Bucherini, E, Silingardi, M, Bianchi, M, Moia, M, Ageno, W, Vandelli, M, Grandone, E, Prandoni, P, Duranti, M, Radicchia, S, Guercini, F, Vedovati, M, Tormene, D, Perlati, M, Barbar, S, Poggio, R, Leischer, L, Galimberti, D, Leone, M, Beretta, A, Carugati, A, Braham, S, Romualdi, E, Tiscia, G, Colaizzo, D, Grilli, M, Siragusa, S, Salvi, R, Miccio, M, Ria, L, Zanatta, N, Poli, D, Camporese, G, Verlato, F, Salvi, A, Nitti, C, Santi, R, Cimminiello, C, Scannapieco, G, Barillari, G, Pasca, S, De Gaudenzi, E, Cappelli, R, Di Minno, G, Tufano, A, Frausini, G, Bova, C, Pogliani, E, Signorelli, S, Testa, S, Alatri, A, Mancuso, G, Grifoni, S, Lodigiani, C, Vedovati, MC, Leone, MF, Signorelli, SS, Lodigiani, C., and BIANCHI, MARCO STEFANO

Abstract

BACKGROUND: About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown. METHODS:In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome. RESULTS:Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups. CONCLUSIONS: Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.)

Published
2012

93. Long-Term Psychometric Outcomes of Facial Lipoatrophy Therapy Forty-EightWeek Observational, Nonrandomized Study.

Author

Orlando, G., Guaraldi, G., De Fazio, D., Rottino, A., Grisotti, A., Blini, M., De Santis, G., Pedone, A., Spaggiari, A., Baccarani, A., Vandelli, M., De Paola, M., Comelli, D., Nardini, G., Beghetto, B., Squillace, N., and Esposito, R.

Subjects
PSYCHOMETRICS, SCIENTIFIC observation, HIV infections, CATHETERS, ARTIFICIAL implants, LACTIC acid, POLYACRYLAMIDE, QUESTIONNAIRES, MENTAL depression, ADIPOSE tissues
Abstract

The aim of this observational, prospective, nonrandomized study was to assess long-term psychometric outcomes of surgical treatment of HIV-related facial lipoatrophy. Two hundred ninety-nine participants (70.8 male) consecutively attending the Metabolic Clinic of Modena and Reggio Emilia University from November 2005 to July 2006, undergoing surgical interventions for HIV-related facial lipoatrophy were enrolled. Fifty-four (18.1) underwent facial lipofilling, which consists of the harvesting of a small, intact parcel of fatty tissue with processing that removes the nonviable components and of the transport of fatty parcels through a small cannula to implant the graft in a manner that provides nutrition and anchors the fat to the host tissue. After an initial lipofilling, 24 (8) needed polylactic acid injections to correct cheek asymmetry, 91 (30.4) received only polylactic acid infiltrations, and 130 (43.5) polyacrylamide infiltrations only. Subjective outcome measures were face aesthetic satisfaction, body image perception, depression evaluated by a visual analogue scale (VAS), the Assessment of Body Change and Distress questionnaire (ABCD), and by the Beck Depression Inventory questionnaire, respectively. Objective measure was cheek thickness evaluated by a 7.5-MHz frequency ultrasound probe perpendicular to the skin surface at the nasolabial fold, the corner of the mouth, the zygomatic arch, and centrally between these points in the buccal fat pad area. Both subjective and objective variables were evaluated at baseline and 48 weeks after end of surgical treatment. All 299 participants had significant improvement of the aesthetic satisfaction for the face (VAS from 2.9 2.1 to 6.2 2.1, p < 0.0001), of body image satisfaction (ABCD question 7 from 3.8 1 to 3.1 1 p < 0.0001 and ABCD question 8 from 70.7 16.7 to 77.2 17.2 p < 0.0001), of depression score (Beck score from 11.4 8.3 to 9.4 7.8 p 0.001). Participants experienced a significant augmentation of both cheeks' thickness (right cheek from 4.3 1.9 mm to 9.5 3 mm p < 0.0001, left cheek from 4.4 2 mm to 9.6 3.1 mm, p < 0.0001). Our data suggest that facial surgery is an important option in the treatment of HIV-related lipoatrophy as an integral part of the management of HIV infection, because of the important and lasting psychological benefits. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results